143 related articles for article (PubMed ID: 12059780)
1. Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities.
Georgieva N; Gadjeva V
Biochemistry (Mosc); 2002 May; 67(5):588-91. PubMed ID: 12059780
[TBL] [Abstract][Full Text] [Related]
2. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
3. New isoniazid derivatives with improved pharmaco-toxicological profile: Obtaining, characterization and biological evaluation.
Dragostin I; Dragostin OM; Samal SK; Dash S; Tatia R; Dragan M; Confederat L; Ghiciuc CM; Diculencu D; Lupușoru CE; Zamfir CL
Eur J Pharm Sci; 2019 Sep; 137():104974. PubMed ID: 31252051
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9.
Bottari B; Maccari R; Monforte F; Ottanà R; Rotondo E; Vigorita MG
Bioorg Med Chem Lett; 2000 Apr; 10(7):657-60. PubMed ID: 10762047
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
7. Reinvestigation of the structure-activity relationships of isoniazid.
Hegde P; Boshoff HIM; Rusman Y; Aragaw WW; Salomon CE; Dick T; Aldrich CC
Tuberculosis (Edinb); 2021 Jul; 129():102100. PubMed ID: 34116482
[TBL] [Abstract][Full Text] [Related]
8. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.
Hearn MJ; Cynamon MH; Chen MF; Coppins R; Davis J; Joo-On Kang H; Noble A; Tu-Sekine B; Terrot MS; Trombino D; Thai M; Webster ER; Wilson R
Eur J Med Chem; 2009 Oct; 44(10):4169-78. PubMed ID: 19524330
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophoric screening of newly synthesized isoniazid derivatives and their antimycobacterial activity.
Naeem S; Akhtar S; Ali Z; Noori MY; Ahmed A
Pak J Pharm Sci; 2018 Mar; 31(2):567-573. PubMed ID: 29618449
[TBL] [Abstract][Full Text] [Related]
10. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
12. Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid.
Silva M; Lara AS; Leite CQ; Ferreira EI
Arch Pharm (Weinheim); 2001 Jun; 334(6):189-93. PubMed ID: 11475908
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
15. The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against
Kazakova OB; Medvedeva NI; Smirnova IE; Lopatina TV; Veselovsky AV
Med Chem; 2021; 17(2):134-145. PubMed ID: 31939731
[TBL] [Abstract][Full Text] [Related]
16. Chitosan-isoniazid conjugates: Synthesis, evaluation of tuberculostatic activity, biodegradability and toxicity.
Berezin AS; Skorik YA
Carbohydr Polym; 2015 Aug; 127():309-15. PubMed ID: 25965488
[TBL] [Abstract][Full Text] [Related]
17. Hepatoprotective effect of isonicotinoylhydrazone SH7 against chronic isoniazid toxicity.
Georgieva N; Gadjeva V; Tolekova A; Dimitrov D
Pharmazie; 2005 Feb; 60(2):138-41. PubMed ID: 15739904
[TBL] [Abstract][Full Text] [Related]
18. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Enhancers of Isoniazid Toxicity in
Lentz F; Reiling N; Martins A; Molnár J; Hilgeroth A
Molecules; 2018 Apr; 23(4):. PubMed ID: 29617279
[TBL] [Abstract][Full Text] [Related]
20. Antitubercular activity of Ru (II) isoniazid complexes.
Aguiar Id; Tavares A; Roveda AC; da Silva AC; Marino LB; Lopes ÉO; Pavan FR; Lopes LG; Franco DW
Eur J Pharm Sci; 2015 Apr; 70():45-54. PubMed ID: 25638418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
